The Society for
Functional Precision Medicine

Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminars which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Alana L. Welm Santhosh Balasubramanian

Our September seminar is Wednesday, November 11, 2020 at 11:00 AM EST, featuring Alana L. Welm, PhD of Huntsman Cancer Institute and Santhosh Balasubramanian of Notable Labs.

Zoom Information


Meeting ID: 936 9981 1786
Password: 351904

 Learn More   Register for Seminar

Recent News

October 22, 2020
Plenary Sesion - A podcast on medicine, oncology, & health policy

Dr Anthony Letai sits down with Dr Vinay Prasad for a an episode of Plenary Session where Dr Letai speaks about precision oncology, the Match trial and NGS in cancer. Be sure to check it out!


August 17, 2020
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse.


July 15, 2020
Tumor Organoids for Functional Precision Oncology

Researchers are using patient-derived tumor organoids to match patients with optimal treatments - When most people think of precision cancer medicine, they think of genomics, with researchers trying to decipher complex gene interactions for the clinical benefit of patients. But according to Dr. Christopher Kemp, a cancer biologist at the Fred Hutchinson Cancer Research Center, that is a narrow view: “[Genomics] is important, but it’s not the whole puzzle by any stretch.”


June 29, 2020
Predicting response to therapy with BH3 profiling - Authored by SFPM President Anthony Letai, PhD

Anthony Letai, PhD gives an overview of how BH3 profiling can be used to predict response to therapy. “There is an enormous amount of actionable information that can be obtained from taking the actual cancer cell you’re interested in and subjecting it to a relevant perturbation, that is, exposing it to the actual drugs,” he said. “We nearly completely overlook this in today’s precision medicine approaches, and I think there is enormous unrealized potential in this general approach.”